J&J again seeks more approvals for clot blocker

(AP)—Johnson & Johnson has given the Food and Drug Administration additional data to on its new anticlotting drug, in a second attempt to get approval for more uses.

Xarelto (zah-RELL'toh) is approved for reducing risk of blood clots in people who've had knee or hip replacement surgery and reducing stroke risk in people with an irregular heartbeat.

J&J sought approval to market Xarelto for preventing a second heart attack or stroke in patients at high risk because of a narrowed heart artery, and for preventing blood clots from forming around stents, tiny metal-mesh scaffolds that prop open heart arteries.

The FDA turned down one application in June. J&J then withdrew the second. Now it's sent the FDA data from a huge study showing Xarelto prevented strokes, attacks and deaths.

Explore further

Bayer drug unproven as stroke preventer: US

Copyright 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Citation: J&J again seeks more approvals for clot blocker (2012, September 7) retrieved 5 December 2021 from https://medicalxpress.com/news/2012-09-jj-clot-blocker.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors